Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Covidien reports positive trial results for new PAD therapies

Covidien reports positive trial results for new PAD therapies

21st October 2013

Covidien has released positive results from two clinical studies assessing new methods of treating peripheral arterial disease (PAD).

Final results from the Durability II trial have demonstrated the safety and effectiveness of the use of a single long EverFlex self-expanding stent for sufferers of this disease.

Meanwhile, encouraging preliminary data from the Definitive AR study have shown early success with the combined use of directional atherectomy and a drug-coated balloon in treating lower limb blockages associated with the condition.

These findings were shared at the Vascular Interventional Advances 2013 conference in Las Vegas and shed light on promising new therapy concepts.

Dr Mark Turco, chief medical officer for Covidien Vascular Therapies, said: "Covidien's extensive clinical research programme in vascular therapies aims to provide rigorous evidence that physicians can use to make treatment decisions for conditions such as peripheral arterial disease."

Last week, the company launched its new Capnostream 20p bedside monitor, a capnography solution that helps to identify serious health threats sooner.ADNFCR-8000103-ID-801651778-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.